- Home
- IONS vs GEO Comparison
IONS vs GEO Comparison
Compare IONS & GEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- GEO
- Stock Information
- Founded
- IONS 1989
- GEO 1984
- Country
- IONS United States
- GEO United States
- Employees
- IONS N/A
- GEO N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- GEO Homebuilding
- Sector
- IONS Health Care
- GEO Consumer Discretionary
- Exchange
- IONS Nasdaq
- GEO Nasdaq
- Market Cap
- IONS 6.0B
- GEO 4.8B
- IPO Year
- IONS 1991
- GEO 1994
- Fundamental
- Price
- IONS $32.32
- GEO $25.33
- Analyst Decision
- IONS Buy
- GEO Buy
- Analyst Count
- IONS 19
- GEO 4
- Target Price
- IONS $61.24
- GEO $46.00
- AVG Volume (30 Days)
- IONS 1.7M
- GEO 2.5M
- Earning Date
- IONS 02-19-2025
- GEO 02-27-2025
- Dividend Yield
- IONS N/A
- GEO N/A
- EPS Growth
- IONS N/A
- GEO N/A
- EPS
- IONS N/A
- GEO 0.27
- Revenue
- IONS $705,000,000.00
- GEO $2,424,264,000.00
- Revenue This Year
- IONS N/A
- GEO $1.44
- Revenue Next Year
- IONS $10.08
- GEO $13.97
- P/E Ratio
- IONS N/A
- GEO $92.39
- Revenue Growth
- IONS N/A
- GEO N/A
- 52 Week Low
- IONS $30.23
- GEO $11.50
- 52 Week High
- IONS $52.34
- GEO $36.46
- Technical
- Relative Strength Index (RSI)
- IONS 48.36
- GEO 32.71
- Support Level
- IONS $30.86
- GEO $26.17
- Resistance Level
- IONS $34.74
- GEO $27.87
- Average True Range (ATR)
- IONS 1.35
- GEO 1.63
- MACD
- IONS 0.18
- GEO -0.36
- Stochastic Oscillator
- IONS 46.34
- GEO 9.80
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About GEO Geo Group Inc (The) REIT
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.